Last $2.56 USD
Change Today 0.00 / 0.00%
Volume 0.0
BIOL On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

biolase inc (BIOL) Snapshot

Open
$2.56
Previous Close
$2.53
Day High
$2.58
Day Low
$2.51
52 Week High
02/24/14 - $3.43
52 Week Low
05/14/14 - $1.69
Market Cap
148.8M
Average Volume 10 Days
89.5K
EPS TTM
$-0.39
Shares Outstanding
58.1M
EX-Date
08/22/05
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOLASE INC (BIOL)

Related News

No related news articles were found.

biolase inc (BIOL) Related Businessweek News

No Related Businessweek News Found

biolase inc (BIOL) Details

BIOLASE, Inc., a biomedical company, develops, manufactures, and markets lasers in dentistry and medicine in the Unites States and internationally. The company offers Waterlase dental laser systems for cutting soft and hard tissue; and diode laser systems, which are used in soft tissue, pain therapy, and cosmetic procedures, such as teeth whitening. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other specialists to perform a range of dental procedures, including cosmetic and complex surgical applications. The company also markets and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intra-oral scanners, and in-office, chair-side milling machines and three-dimensional printers, as well as provides precision intuitive diagnosis and treatment planning solutions. In addition, it offers medical systems comprising Diolase 10 Diode Laser for therapeutic applications consisting of temporary pain relief; topical heating for the purpose of temporarily relieving minor muscle and joint pain and stiffness, minor arthritis pain, muscle spasm, minor sprains and strains, and minor muscular back pain; temporarily increasing local blood circulation; and temporarily relaxing muscles. Further, the company manufactures and sells disposable products and accessories for laser systems, as well as markets flexible fibers and hand pieces. BIOLASE, Inc. has a strategic agreement with Valam, Inc. to develop, market, and sell office-based laser systems to otolaryngologists. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Irvine, California.

220 Employees
Last Reported Date: 03/17/14
Founded in 1984

biolase inc (BIOL) Top Compensated Officers

Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $205.4K
Vice President of Research and Development
Total Annual Compensation: $250.0K
Director of Professional Relations
Total Annual Compensation: $90.0K
Compensation as of Fiscal Year 2013.

biolase inc (BIOL) Key Developments

BIOLASE, Inc. Introduces the EPIC X Diode Laser

BIOLASE, Inc. introduced the EPIC X diode laser, the company's premier and most complete diode laser for the whole dental team. Following up on the success of the company's EPIC 10, released in 2012, EPIC X features upgrades and improvements to ensure the best dental experience possible for dentists, their staff members and their patients. Additionally, EPIC X includes enhancements to nearly every system component to optimize treatment speed and efficiency. EPIC X offers faster procedures for three unique treatment modes -- Surgery, Whitening and Pain Relief -- all of which generate a strong return on investment, create happy patients and provide professional satisfaction. Pre-initiated tips, which are available for BIOLASE diode laser systems only, are a breakthrough because they eliminate a time-consuming task and guarantee a consistent, predictable tip condition for soft tissue surgery. The EPIC X also offers a new Reliability Assurance Plan for every EPIC X customer to ensure they are never without an EPIC X laser for more than 24 hours. This assures customers the peace of mind that they will have maximum uptime and ongoing access to the exceptional clinical and economic outcomes offered by EPIC X.

Biolase Announces Resignation of Alexander K. Arrow as Chief Medical Officer Effective December 3, 2014

BIOLASE, Inc. reported that Alexander K. Arrow, M.D. has resigned as Chief Medical Officer and will be leaving the Company effective December 3, 2014 to pursue other opportunities. Dr. Arrow joined the BIOLASE Board of Directors in July 2010. He remained on the Board and served as chairman of the Audit and Compensation committees until June 2013. In June 2013, he was named President and Chief Operating Officer and he served in that role until he was appointed Chief Medical Officer in September of this year.

BIOLASE, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

BIOLASE, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company's net revenue was $12,714,000 compared to $12,345,000 a year ago. Loss from operations was $3,295,000 compared to $3,861,000 a year ago. Loss before income tax benefit was $3,467,000 compared to $4,027,000 a year ago. Net loss was $3,495,000 compared to $4,049,000 a year ago. Diluted net loss per share was $0.08 compared to $0.12 a year ago. Non-GAAP net loss was $2,952,000 compared to $3,150,000 a year ago. Non-GAAP net loss per share, basic and diluted was $0.07 compared to $0.10 a year ago. These positives were partially offset by a decrease in domestic and international laser systems revenue, and a slight decrease in consumables and other revenue. For the nine months, the company's net revenue was $34,418,000 compared to $41,189,000 a year ago. Loss from operations was $14,122,000 compared to $8,970,000 a year ago. Loss before income tax benefit was $14,740,000 compared to $9,430,000 a year ago. Net loss was $14,821,000 compared to $9,248,000 a year ago. Diluted net loss per share was $0.38 compared to $0.29 a year ago. Non-GAAP net loss was $12,749,000 compared to $7,115,000 a year ago. Non-GAAP net loss per share, basic and diluted was $0.33 compared to $0.22 a year ago. The overall decrease in period-over-period net revenue resulted from decreases in domestic and international laser system revenue, imaging systems revenue, and consumables and other net revenue, partially offset by the recognition of deferred training service revenues due to a change in estimate in the period over which deferred training service revenue is being recognized.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOL:US $2.56 USD 0.00

BIOL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bacterin International Holdings Inc $3.23 USD 0.00
Cutera Inc $13.61 USD 0.00
STAAR Surgical Co $5.86 USD 0.00
Stereotaxis Inc $1.62 USD 0.00
SurModics Inc $22.28 USD 0.00
View Industry Companies
 

Industry Analysis

BIOL

Industry Average

Valuation BIOL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.2x
Price/Book 10.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOLASE INC, please visit www.biolase.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.